Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lechner, K.
Right arrow Articles by Kalhs, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lechner, K.
Right arrow Articles by Kalhs, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 10:S45-S51, 1999
© 1999 European Society for Medical Oncology

Reviews

Treatment of acute leukemia

K. Lechner, K. Geissler, U. Jäger, H. Greinix and P. Kalhs

Department of Internal Medicine, Division of Hematology/Blood Coagulation, and Bone Marrow Transplantation Unit, University of Vienna Austria

Correspondence to: Prof. Dr. Klaus Lechner I. Department of Internal Medicine, Division of Hematology/Blood Coagulation, Waehringer Guertel 18-20, A - 1090 Vienna, Austria. e-mail: klaus.lechner{at}akh-wien.ac.at

Leukemic cells are highly sensitive to chemotherapeutic agents. A reduction of the leukemic burden is easily achieved by chemotherapy in most cases. However, it is difficult to reduce the number of leukemic cells to such an extent that a regrowth does not occur and the patient is cured.

Traditionally the therapy of acute leukemia is divided into induction and post remission therapy. The aim of the induction therapy is to reduce the number of leukemic cells to a morphologically undetectable level allowing normal hemopoiesis to recover. The goal of the post remission treatment is a further reduction of leukemic cells to zero or to very low levels which can be controlled by (still unknown) endogenous mechanisms. In some recent treatment protocols induction and the early part of post remission treatment are not strictly separated.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
D. Cervi, G. Klement, D. Stempak, S. Baruchel, A. Koki, and Y. Ben-David
Targeting Cyclooxygenase-2 Reduces Overt Toxicity toward Low-Dose Vinblastine and Extends Survival of Juvenile Mice with Friend Disease
Clin. Cancer Res., January 15, 2005; 11(2): 712 - 719.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.